These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19632960)

  • 1. HIV-HCV Co-infection therapeutic outcomes have not improved over time.
    Cooper C; Costiniuk C; Giguère P
    HIV Clin Trials; 2009; 10(3):203-6. PubMed ID: 19632960
    [No Abstract]   [Full Text] [Related]  

  • 2. Highlights of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
    Prescott LM
    Body Posit; 2002 Dec; 15(7):16-20. PubMed ID: 14989207
    [No Abstract]   [Full Text] [Related]  

  • 3. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection.
    Fialaire P; Payan C; Vitour D; Chennebault JM; Loison J; Pichard E; Lunel F
    J Infect Dis; 1999 Aug; 180(2):574-5. PubMed ID: 10395889
    [No Abstract]   [Full Text] [Related]  

  • 4. Human immunodeficiency virus (HIV) protease inhibitors have no effect on hepatitis C virus (HCV) serum levels of HIV-HCV co-infected patients.
    Matsiota-Bernard P; Vrioni G; Onody C; Bernard L; de Truchis P; Peronne C
    Int J Antimicrob Agents; 2001 Feb; 17(2):155-7. PubMed ID: 11165122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfected with HIV and HCV].
    Gavazzi G; Richallet G; Morand P; Bouchard O; Bosseray A; Leclercq P; Micoud M
    Pathol Biol (Paris); 1998 Jun; 46(6):412-5. PubMed ID: 9769871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switch study of nevirapine.
    AIDS Patient Care STDS; 2000 Dec; 14(12):672. PubMed ID: 11187109
    [No Abstract]   [Full Text] [Related]  

  • 7. Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine.
    Crane HM; Van Rompaey SE; Kitahata MM
    AIDS Patient Care STDS; 2007 Dec; 21(12):920-9. PubMed ID: 18154489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral triple therapy decreases HIV viral load but does not alter hepatitis C virus (HCV) serum levels in HIV-HCV-co-infected haemophiliacs.
    Rockstroh JK; Theisen A; Kaiser R; Sauerbruch T; Spengler U
    AIDS; 1998 May; 12(7):829-30. PubMed ID: 9619824
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of first antiretroviral treatment duration and outcome in HIV, HIV-HBV and HIV-HCV infection.
    Cooper CL; Mills E
    Int J STD AIDS; 2007 Aug; 18(8):546-50. PubMed ID: 17686217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study to investigate the impact of the initiation of highly active antiretroviral therapy on the hepatitis C virus viral load in HIV/HCV-coinfected patients.
    Mijch A; Sasadeusz J; Hellard M; Dunne M; McCaw R; Bowden S; Gowans EJ
    Antivir Ther; 2005; 10(2):277-84. PubMed ID: 15865222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substitution for protease inhibitors in HIV therapy.
    Mikhail E
    N Engl J Med; 2003 Dec; 349(25):2460-1; author reply 2460-1. PubMed ID: 14689602
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
    Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
    J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV, HAART, and hyperlipidemia: balancing the effects.
    Sherer R
    J Acquir Immune Defic Syndr; 2003 Oct; 34 Suppl 2():S123-9. PubMed ID: 14703941
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3.
    Rachlis A; Clotet B; Baxter J; Murphy R; Lefebvre E
    HIV Clin Trials; 2007; 8(4):213-20. PubMed ID: 17720661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four-drug regimens may be better.
    AIDS Patient Care STDS; 2000 Dec; 14(12):671. PubMed ID: 11119435
    [No Abstract]   [Full Text] [Related]  

  • 19. Associations between lipodystrophy or antiretroviral medications and cirrhosis in patients with HIV infection or HIV/HCV coinfection.
    Ioannou GN; Bryson CL; Weiss NS; Boyko EJ
    Eur J Gastroenterol Hepatol; 2015 May; 27(5):577-84. PubMed ID: 25769096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.
    Introcaso CE; Hines JM; Kovarik CL
    J Am Acad Dermatol; 2010 Oct; 63(4):549-61; quiz 561-2. PubMed ID: 20846563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.